NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it will collaborate with the Moffitt Cancer Center on the development of a microRNA-based diagnostic for thyroid neoplasia.

According to Rosetta, between four and seven percent of the general population develops thyroid nodules, but fewer than 10 percent of these are malignant. Fine needle aspiration (FNA) is routinely conducted to obtain tissue for biopsy, but analyses of these samples are often inconclusive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.